ClinicalTrials.gg
RecruitingNCT06790693INAVO123Updated Nov 4, 2026

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

A Phase 3 interventional study of Inavolisib and Placebo in Breast Cancer, sponsored by Hoffmann-La Roche. Recruiting at 242 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 4, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inavolisib in Breast Neoplasms — 12 open to participants now, 15 under way, 4 of them phase 3. inavolisib · Breast Neoplasms.

Planned enrollment
3rd of 16
450 · median 185
Started
2025
with 2 others
Phase 3
3 of 16
3 open now
Primary completion
2032-01
later than 14 of 14 live
Registered
10th of 16
by date
Lead sponsor
9 of 16
Hoffmann-La Roche

Among the 16 studies testing inavolisib in Breast Neoplasms, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 14 of the 14 other live ones, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 16 studies testing inavolisib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About inavolisib

inavolisib: first FDA approval 2024 (ITOVEBI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inavolisib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women or men with or cytologically confirmed carcinoma of the breast
  • Documented ER-positive and/or progesterone receptor-positive tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
  • Documented -negative tumor according to ASCO/CAP guidelines
  • De-novo HR+ , HER2- ABC, or, alternatively, HR+ , HER2- ABC after at least 2 years of standard /adjuvant endocrine therapy without disease progression during that treatment and disease-free interval of at least 1 year since the completion of that treatment
  • Participants who have bilateral breast cancers which are both HR-positive and HER2-negative
  • Confirmation of biomarker eligibility
  • Consent to provide fresh or specimen
  • per , Version 1.1 (RECIST v1.1)
  • (ECOG) Performance Status of 0 or 1
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which is required
  • Metaplastic breast cancer
  • Any prior systemic therapy for locally advanced unresectable or breast cancer
  • Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
  • Any history of or carcinomatous meningitis
  • Known and untreated, or active . Participants with a history of treated CNS metastases are eligible
  • Active inflammatory or infectious conditions in either eye or history of idiopathic or -associated uveitis in either eye
  • Symptomatic active lung disease
  • History of or active inflammatory bowel disease
  • Any active bowel inflammation
  • Prior hematopoietic stem cell or bone marrow transplantation
  • Treatment with strong cytochrome P450 (CYP) 3A4 inhibitors or strong inducers within 4 weeks or 5 drug-elimination half-lives, prior to initiation of study treatment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Inavolisib + Letrozole + CDK4/6i

    Participants will receive inavolisib, letrozole and CDK4/6i.

    Drug: Inavolisib · Drug: CDK4/6i · Drug: Letrozole

  • Placebo comparator
    Placebo + Letrozole + CDK4/6i

    Participants will receive placebo, letrozole and CDK4/6i.

    Drug: Placebo · Drug: CDK4/6i · Drug: Letrozole

Interventions

  • Participants will receive oral inavolisib once daily (QD).

    Also known as: GDC-0077, Itovebi

  • DrugPlacebo

    Participants will receive oral placebo QD.

  • DrugCDK4/6i

    Participants will receive CDK4/6i on either Days 1-21 or Days 1-28 of each 28-day cycle.

  • Participants will receive oral letrozole QD.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 7 years)

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From randomization to death from any cause (up to 7 years)

  2. Investigator-assessed Objective Response Rate (ORR)

    Time frame: Up to 7 years

  3. Investigator-assessed Duration of Response (DOR)

    Time frame: From the first occurrence of a confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 7 years)

  4. Investigator-assessed Clinical Benefit Rate (CBR)

    Time frame: Up to 7 years

  5. Time to Confirmed Deterioration (TTCD) in Pain

    Time frame: From baseline until end of follow-up (up to 7 years)

  6. TTCD in Physical Function

    Time frame: From baseline until end of follow-up (up to 7 years)

  7. TTCD in Role Function

    Time frame: From baseline until end of follow-up (up to 7 years)

  8. TTCD in Global Health Status

    Time frame: From baseline until end of follow-up (up to 7 years)

  9. Percentage of Participants with Adverse Events

    Time frame: From baseline until end of follow-up (up to 7 years)

  10. Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: Up to 7 years

  11. Number of Participants Reporting Each Response Option for Treatment Side-effect Bother Single-item General Population, Question 5 (GP5) from the Functional Assessment of Cancer Therapy-General Questionnaire; (FACT-G)

    Time frame: Up to 7 years

  12. Change from Baseline in Symptomatic Treatment Toxicities as Assessed Through use of the PRO-CTCAE

    Time frame: Baseline up to 7 years

  13. Change from Baseline in Treatment Side-effect Bother as Assessed Through use of the FACT-G GP5 Item

    Time frame: Baseline up to 7 years

07

Study locations

239 of 242 sites recruiting

Showing the first 100 of 242 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2032, 81 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 81 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 24, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Jan 31, 2032
CompletionEst.
Feb 1, 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Caritas Klinik St. Theresia -Frauenklinik Brustzentrum is now Withdrawn
Show site
  • New York Cancer & Blood Specialists · Shirley, United States
across 2 updates, Oct 6, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Caritas Klinik St. Theresia -Frauenklinik Brustzentrum is now Withdrawn
    + 1 other change: verification date
  2. Oct 6, 2026
    1 site added
    Show site
    • New York Cancer & Blood Specialists · Shirley, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06790693
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Apr 9, 2025
Primary completion
Jan 31, 2032 (estimated)
Completion
Feb 1, 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

Reference Study ID Number: WO45654 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion